Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
283
datasets available to search
ShareScore release 0.7.1
Dataset results
283 results for “ITP”
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
ClinicalTrials.gov study NCT03395210. IPD Sharing: YES. Countries: 8. Publications: 4.
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
ClinicalTrials.gov study NCT04562766. IPD Sharing: YES. Countries: 26. Publications: 3.
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
ClinicalTrials.gov study NCT01762761. IPD Sharing: YES. Countries: 1. Publications: 1.
A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
ClinicalTrials.gov study NCT03524612. IPD Sharing: YES. Countries: 15. Publications: 1.
Mapped Industrial Tree Plantations (ITP) in Caraga Region, Mindanao, Philippines for the Year 2019
<p>The Esri Shapefile, in UTM 51 WGS 1984 coordinate reference system, contains polygons of industrial tree plantation species (Falcata, Bagras, Yemane, and Mangium) in the Caraga Region, Mindanao, Philippines. The plantations were mapped through the classification of year 2019 Sentinel-2 satellite images, complemented by high-resolution satellite images available in Google Earth, as well as field surveys conducted between October 1, 2019 to September 30, 2021.</p> <p>Please refer to the Project 1 terminal report (<a href="../records/13735736" target="_blank" rel="noopener">https://zenodo.org/records/13735736</a>) for more details.</p>
Supplementary material for the ITP'23 article "Lessons for Interactive Theorem Proving Researchers from a Survey of Coq Users"
<p>This artifact contains the supplementary files for the ITP'23 article "Lessons for Interactive Theorem Proving Researchers from a Survey of Coq Users". More specifically, it contains:</p> <ul> <li>the Limesurvey structure exported file (<code>Limesurvey/survey-structure.lss</code>);</li> <li>the HTML print of the survey in English and Chinese (<code>Limesurvey/questionnaire_english.html</code> and <code>Limesurvey/questionnaire_chinese.html</code>);</li> <li>the Jupyter notebook (<code>Coq-survey-analysis.ipynb</code>) and the Stata code (<code>regressions/Regressions_and_Romano-Wolf.do</code>) that were used to produce the results;</li> <li>the plots for the answers to all the closed questions, as well as plots for some interactions between answers to multiple closed questions in <code>png</code> and <code>svg</code> formats (<code>assets/</code>);</li> <li>manual analysis of some open text questions (<code>coded_answers/</code>);</li> <li>answers to open text questions (<code>open_answers/</code>).</li> </ul> <p>This artifact does <em>not</em> contain the full raw data from the survey. These data have been deleted, following the GDPR compliance statement that was displayed at the beginning of the survey. The open text answers that are made available through this artifact have been sanitized to remove any personally identifiable element.</p> <p>File listing</p> <ul> <li>README.md: this README</li> <li>Limesurvey <ul> <li>questionnaire_english.html: survey HTML print in English</li> <li>questionnaire_chinese.html: survey HTML print in Chinese</li> <li>survey-structure.lss: Limesurvey structure export</li> </ul> </li> <li>Coq-survey-analysis.ipynb: Jupyter notebook used to produce plots</li> <li>regressions <ul> <li>Regressions_and_Romano-Wolf.do: Stata code used to do the regressions appearing in the article</li> </ul> </li> <li>assets <ul> <li>many <code>png</code> and <code>svg</code> files for plots showing quantitative results</li> </ul> </li> <li>coded_answers <ul> <li>renaming.md: manual analysis of the answers to the open text question "If you wish to elaborate on why Coq should / should not be renamed, feel free to do it here."</li> <li>renaming_choices.md: manual analysis of the answers to the open text question "If you wish to share any specific arguments in favor or against some specific name choices, please do so here."</li> <li>contributing_experience.csv: answers to the open text question "Feel free to elaborate on the contributing experience, what we can do better, or why you do not contribute." with manual analysis</li> <li>doc_improvements-grouped.docx manual analysis of the answers to the open text question "Feel free to elaborate on any of the items listed above, their importance, etc. Are there other improvements that you think would be important?" (in the context of a question on "How important are improvements to the following aspects of the Coq documentation?")</li> </ul> </li> <li>open_answers: Each table has been reordered and has a different indexing, so relating answers from different tables is not possible. Furthermore, answers have been checked and sanitized to remove any personally identifiable elements. <ul> <li>ci_feedback.csv: answers to the question "If you have general feedback on CI in the Coq ecosystem, feel free to share it here." Also shared at: <a href="https://github.com/coq-community/manifesto/issues/141">https://github.com/coq-community/manifesto/issues/141</a></li> <li>contributing_experience.csv: answers to the question "Feel free to elaborate on the contributing experience, what we can do better, or why you do not contribute."</li> <li>coqide_improvements.csv: answers to the question "What improvements, bug fixes and new features would you most like to see in CoqIDE?" Also shared at: <a href="https://github.com/coq/coq/issues/16580">https://github.com/coq/coq/issues/16580</a></li> <li>coq_improvements.csv: answers to the question "Feel free to elaborate on any of the items listed above, their importance, etc. Are there other improvements that you think would be important? Also, feel free to tell us how Coq does compared to other proof assistants you have experience with." (in the context of a question on "In order to make you more productive in Coq and to encourage others to learn and use Coq, how important are improvements in the following areas?")</li> <li>coqtail_improvements.csv: answers to the question "What improvements, bug fixes and new features would you most like to see in Coqtail?" Also shared at: <a href="https://github.com/whonore/Coqtail/issues/277">https://github.com/whonore/Coqtail/issues/277</a></li> <li>distracting_company_coq_features.csv</li> <li>doc_improvements.csv: answers to the question "Feel free to elaborate on any of the items listed above, their importance, etc. Are there other improvements that you think would be important?" (in the context of a question on "How important are improvements to the following aspects of the Coq documentation?")</li> <li>extraction_targets.csv: answers to the question "If you're interested in new extraction targets, which languages do you want?" Also analyzed quantitatively in: assets/extraction-targets-barplot.png</li> <li>jscoq_improvements.csv: answers to the question "What improvements, bug fixes and new features would you most like to see in jsCoq?" Also shared at: <a href="https://github.com/jscoq/jscoq/issues/261">https://github.com/jscoq/jscoq/issues/261</a></li> <li>jupyter_improvements.csv: answers to the question "What improvements, bug fixes and new features would you most like to see in coq_jupyter?" Also shared at: <a href="https://github.com/EugeneLoy/coq_jupyter/issues/46">https://github.com/EugeneLoy/coq_jupyter/issues/46</a></li> <li>jupyter_support.csv: answers to the question "Have you had any issues or lack of support for coq_kernel for any service? If so, feel free to share here." Also shared at: <a href="https://github.com/EugeneLoy/coq_jupyter/issues/46">https://github.com/EugeneLoy/coq_jupyter/issues/46</a></li> <li>languages.csv: answers to the question "What languages would be the most useful to support?" Also analyzed quantitatively in: assets/languages-barplot.png</li> <li>learning_experience.csv: answers to the question "How was your experience while learning Coq? For example, what were the easiest and/or most difficult parts of the process? Do you have suggestions to improve the experience?"</li> <li>proof_general_customizations.csv: answers to the question "Do you use specific customizations or fixups of Proof General or Company-Coq (in your ~/.emacs)? If yes, briefly speaking, what are these customizations and would you like to have some of them applied by default?" Also shared at: <a href="https://github.com/ProofGeneral/PG/issues/671">https://github.com/ProofGeneral/PG/issues/671</a></li> <li>proof_general_improvements.csv: answers to the question "What improvements, bug fixes and new features would you most like to see in Proof General?" Also shared at: <a href="https://github.com/ProofGeneral/PG/issues/671">https://github.com/ProofGeneral/PG/issues/671</a></li> <li>renaming.csv: answers to the question "If you wish to elaborate on why Coq should / should not be renamed, feel free to do it here."</li> <li>renaming_choices.csv: answers to the question "If you wish to share any specific arguments in favor or against some specific name choices, please do so here."</li> <li>survey_issues.csv: answers to the question "Did you encounter any issues with the survey that you'd like to report or do you have other feedback that we should hear about?"</li> <li>vim_compatibility.csv: answers to the question "What Vim / NeoVim features or plugins would you like to have better integrated with Coqtail? " Also shared at: <a href="https://github.com/whonore/Coqtail/issues/277">https://github.com/whonore/Coqtail/issues/277</a></li> <li>vscoq_improvements.csv: answers to the question "What improvements, bug fixes and new features would you most like to see in VsCoq?" Also shared at: <a href="https://github.com/coq-community/vscoq/issues/308">https://github.com/coq-community/vscoq/issues/308</a></li> </ul> </li> </ul>
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
ClinicalTrials.gov study NCT01444417. IPD Sharing: Not stated. Countries: 3. Publications: 1.
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
ClinicalTrials.gov study NCT00770562. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
ClinicalTrials.gov study NCT05369208. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
ClinicalTrials.gov study NCT00540423. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
ClinicalTrials.gov study NCT01143038. IPD Sharing: Not stated. Countries: 9. Publications: 4.
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
ClinicalTrials.gov study NCT00220727. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
ClinicalTrials.gov study NCT02076399. IPD Sharing: NO. Countries: 8. Publications: 1.
Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
ClinicalTrials.gov study NCT00908037. IPD Sharing: Not stated. Countries: 6. Publications: 3.
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
ClinicalTrials.gov study NCT02279173. IPD Sharing: YES. Countries: 17. Publications: 2.
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
ClinicalTrials.gov study NCT00774202. IPD Sharing: YES. Countries: 1. Publications: 1.
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
ClinicalTrials.gov study NCT02077192. IPD Sharing: NO. Countries: 15. Publications: 1.
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
ClinicalTrials.gov study NCT00370331. IPD Sharing: Not stated. Countries: 25. Publications: 6.
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
ClinicalTrials.gov study NCT01098487. IPD Sharing: Not stated. Countries: 11. Publications: 1.
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
ClinicalTrials.gov study NCT03939637. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.